Featured Archives - Page 7 of 15 - Halberd Corporation

Sep 13 2021

Halberd’s Treatment Eradicates Primary Building Block of Alzheimer’s Disease

By Admin|2021-09-12T21:20:30-04:00September 13th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 13, 2021 – Halberd Corporation (OTC PINK:HALB) has successfully eradicated the primary building block of neurofibrillary tangles of Alzheimer’s Disease from test fluids in laboratory testing. Through its patented extracorporeal process in combination with its patent-pending laser eradication process, replication tests conducted at Youngstown State University (YSU) achieved virtually 100% elimination ...

Sep 8 2021

Halberd Corporation Appoints Anthony Mirabelli Vice-President, Mergers & Acquisitions

By Admin|2021-09-07T20:16:32-04:00September 8th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 8, 2021 – Halberd Corporation (OTC PINK:HALB) announced the appointment of Anthony Mirabelli to the position of Vice-President, Mergers & Acquisitions. Mirabelli will be responsible for negotiating joint ventures, license agreements and other activities whereby Halberd can capitalize on his vast experience in pharmaceutical and medical device development and sales. Anthony ...

Aug 30 2021

Halberd Corporation Alzheimer’s Disease Treatment Tests Yield Outstanding Results

By Admin|2021-08-29T20:56:56-04:00August 30th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, August 30, 2021 – Halberd Corp. (OTC PINK:HALB) provided an update on its Alzheimer’s Disease eradication experimentation being conducted at Youngstown State University (YSU) and Arizona State University (ASU). Following standard scientific methodology, Halberd conducted two rounds of experimentation on Phosphorylated Tau, and the results were so astounding that the researchers want ...

Aug 25 2021

Halberd Receives Patent for Treatment of Cockayne Syndrome — May Provide Pathway to Slow Aging

By Admin|2021-08-24T20:42:26-04:00August 25th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, August 25, 2021 – Halberd Corporation (OTC-PINK: "HALB") received notification from the Ference Law Firm in Pittsburgh of a Notice of Allowance, by the US Patent Office, for the treatment of Cockayne Syndrome. Cockayne Syndrome is a fatal autosomal recessive neurodegenerative disorder which causes premature aging and severely impaired development of the ...

Aug 23 2021

Halberd Files Provisional Patent Application – Furthering Efforts on Alzheimer’s Disease

By Admin|2021-08-22T21:05:51-04:00August 23rd, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, August 23, 2021 – Halberd Corp. (OTC PINK: "HALB") announced filing a U. S. joint provisional patent application, “Treating Alzheimer’s Disease Utilizing Extracorporeal Radio Frequency.” The innovation is a result of Halberd’s Sponsored Research conducted at Arizona State University (ASU) and Youngstown State University (YSU). The provisional patent application covers technology developed ...

Aug 18 2021

Halberd Corporation’s VITA-SHIELD-MAX(TM) Available. Buy Now!

By Admin|2021-09-28T10:26:44-04:00August 18th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, August 18, 2021 – Halberd Corporation’s (OTC-PINK: "HALB") Nutraceutical product, Vita-Shield-MaxTM is now available on www.vitashieldmax.com. Vita-Shield-MaxTM is a specially formulated Nutraceutical to help maintain a healthy immune system. William A. Hartman, Halberd's Chairman, President & CEO, stated, “Halberd Corporation’s scientists put extensive research into the precise formulation of this neutraceutical product ...

Aug 16 2021

Halberd’s Disease Elimination Technology R&D at Youngstown State University (YSU) Draws Attention of CBS Affiliate WKBN

By Admin|2021-08-15T14:11:44-04:00August 16th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, August 16, 2021 – Halberd Corporation’s (OTC-PINK: "HALB") research at Youngstown State University (YSU) caught the attention of Youngstown, OH TV news station, WKBN, a CBS affiliate. The station’s 5:00PM newscast on Friday, August 13, 2021, included a segment on Halberd’s on-going research and testing of its groundbreaking, patent protected technology at ...

Aug 9 2021

Halberd Corporation’s VITA-SHIELD-MAX(TM) Immunity Support Product Shipped

By Admin|2021-08-08T15:07:13-04:00August 9th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, August 9, 2021 – Halberd Corporation (OTC-PINK: "HALB") reports Vita-Shield-MaxTM, has been shipped! With Covid-19 cases back on the rise fueled by the Delta Variant, this “Immunity Support Nutraceutical Product” is arriving at the right time. William A. Hartman, Halberd's Chairman, President & CEO, stated, “We will shortly begin selling Vita-Shield-MaxTM and ...

Jul 28 2021

Halberd Corporation Successfully Establishes Disease Eradication Proof-of-Concept – “Never Before Accomplished”

By Admin|2021-07-27T17:35:26-04:00July 28th, 2021|Featured, Investor News, News|0 Comments

A Major Step Towards the Elimination of Multiple Infectious Diseases and Possible Treatment for Alzheimer’s Disease/PTSD/CTE Jackson Center, PA, July 28, 2021 – Halberd Corporation (OTC-PINK: "HALB") establishes “proof of concept” taking a major step towards the elimination of multiple infectious diseases, such as, malaria, tuberculosis, sepsis, meningitis, and pandemics, among others, by successfully eliminating ...

Jul 22 2021

Halberd Corp. Advances the Elimination of Antigens Present in Alzheimer’s Disease & PTSD/Chronic Traumatic Encephalopathy

By Admin|2021-07-21T19:48:45-04:00July 22nd, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, July 22, 2021 – Halberd Corporation (OTC-PINK: "HALB") confirms the shipment of samples of metallic nanoparticles conjugated to Alzheimer’s Disease (AD) antibodies, Tau and Phosphorylated Tau. Having successfully conjugated the metallic nanoparticles (via its breakthrough patent-pending process), GreenBioAZ shipped the materials to Youngstown State University (YSU). At YSU, Dr. William G. Sturrus, ...

Previous 678 Next